Page last updated: 2024-11-04

rofecoxib and Stroke

rofecoxib has been researched along with Stroke in 36 studies

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

ExcerptRelevanceReference
"To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia."9.05Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020)
"The association between rofecoxib use and ischemic stroke has not been shown in clinical trials."7.74Long-term risk of ischemic stroke associated with rofecoxib. ( Afilalo, J; Coussa-Charley, MJ; Eisenberg, MJ, 2007)
"To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia."5.05Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020)
"Overall, the use of NSAIDs is not associated with an increased risk of hemorrhagic stroke, although this risk was modestly significantly elevated in diclofenac and meloxicam users."4.93Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. ( Matteson, EL; Thongprayoon, C; Ungprasert, P, 2016)
"It can be postulated that in addition to the risk of heart attack and stroke, rofecoxib users were at increased risk of hemorrhage, in addition to other thrombotic and embolic adverse events, which was exacerbated in those taking blood thinners or NSAIDs."3.75Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. ( Barry, WT; Bottone, FG, 2009)
" Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0."3.75Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009)
" Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index."3.74Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008)
"The association between rofecoxib use and ischemic stroke has not been shown in clinical trials."3.74Long-term risk of ischemic stroke associated with rofecoxib. ( Afilalo, J; Coussa-Charley, MJ; Eisenberg, MJ, 2007)
"Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam."3.73Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006)
"Rofecoxib use was associated with acute cerebrovascular events (Empirical Bayes Geometric Mean ratio 1."1.35Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. ( Cheng, H; Curtis, JR; Delzell, E; Dumouchel, W; Fram, D; Kilgore, M; Saag, K; Yun, H, 2008)
"Celecoxib and naproxen were not associated with increased risks."1.35Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. ( Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J, 2008)
"Among 7."1.33Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? ( Coupal, L; Grover, SA; Zowall, H, 2005)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's31 (86.11)29.6817
2010's3 (8.33)24.3611
2020's2 (5.56)2.80

Authors

AuthorsStudies
Moore, N1
Jordan, F1
Quinn, TJ1
McGuinness, B1
Passmore, P1
Kelly, JP1
Tudur Smith, C1
Murphy, K1
Devane, D1
Zhang, Y1
Hoda, MN1
Zheng, X1
Li, W1
Luo, P1
Maddipati, KR1
Seki, T1
Ergul, A1
Wang, MH1
Ungprasert, P1
Matteson, EL1
Thongprayoon, C1
Nadareishvili, Z1
Michaud, K1
Hallenbeck, JM1
Wolfe, F1
Curtis, JR1
Cheng, H1
Delzell, E1
Fram, D1
Kilgore, M1
Saag, K1
Yun, H1
Dumouchel, W1
Bottone, FG1
Barry, WT1
Ray, WA1
Varas-Lorenzo, C1
Chung, CP1
Castellsague, J1
Murray, KT1
Stein, CM1
Daugherty, JR1
Arbogast, PG1
García-Rodríguez, LA1
Bäck, M1
Yin, L1
Ingelsson, E1
Topol, EJ2
Couzin, J2
Lenzer, J2
Sibbald, B1
Pemberton, MN1
Grover, SA1
Coupal, L1
Zowall, H1
Giaquinta, D1
Dyer, C1
Fendrick, AM1
Idänpään-Heikkilä, JE1
Klaukka, T1
Karha, J1
Weinberg, JM1
Wadman, M1
Huang, WF1
Hsiao, FY1
Tsai, YW1
Wen, YW1
Shih, YT1
Avorn, J1
Roth-Cline, MD1
Nelson, NJ1
Höer, A1
Häussler, B1
Chou, R1
Fu, R1
Carson, S1
Saha, S1
Helfand, M1
Afilalo, J1
Coussa-Charley, MJ1
Eisenberg, MJ1
Andersohn, F1
Cunnington, M1
Webb, D1
Qizilbash, N1
Blum, D1
Mander, A1
Funk, MJ1
Weil, J1
Josefson, D1
Schnitzer, TJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073]Phase 2/Phase 384 participants (Actual)Interventional2017-04-04Completed
Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645]Phase 260 participants (Actual)Interventional2006-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for rofecoxib and Stroke

ArticleYear
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
    Drug safety, 2020, Volume: 43, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 I

2020
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
    The Cochrane database of systematic reviews, 2020, 04-30, Volume: 4

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age

2020
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
    Stroke, 2016, Volume: 47, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprof

2016
Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions.
    Journal of clinical epidemiology, 2007, Volume: 60, Issue:1

    Topics: Biomedical Research; Cyclooxygenase 2 Inhibitors; Endarterectomy, Carotid; Humans; Lactones; Researc

2007

Other Studies

32 other studies available for rofecoxib and Stroke

ArticleYear
Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2014, Sep-15, Volume: 307, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Cell Line, Tumor; Cell Prol

2014
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
    Arthritis and rheumatism, 2008, Aug-15, Volume: 59, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An

2008
Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example.
    Medical care, 2008, Volume: 46, Issue:9

    Topics: Adverse Drug Reaction Reporting Systems; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal;

2008
Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
    Current medical research and opinion, 2009, Volume: 25, Issue:6

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Drug Interactions; Dr

2009
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C

2009
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
    European heart journal, 2012, Volume: 33, Issue:15

    Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic

2012
Failing the public health--rofecoxib, Merck, and the FDA.
    The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17

    Topics: Adverse Drug Reaction Reporting Systems; Advertising; Arthritis, Rheumatoid; Clinical Trials as Topi

2004
Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
    Science (New York, N.Y.), 2004, Oct-15, Volume: 306, Issue:5695

    Topics: Blood Pressure; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; Drug and Narcot

2004
US government agency to investigate FDA over rofecoxib.
    BMJ (Clinical research ed.), 2004, Oct-23, Volume: 329, Issue:7472

    Topics: Drug Approval; Humans; Interprofessional Relations; Lactones; Myocardial Infarction; Stroke; Sulfone

2004
Rofecoxib (Vioxx) voluntarily withdrawn from market.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, Oct-26, Volume: 171, Issue:9

    Topics: Drug and Narcotic Control; Drug Industry; Humans; Lactones; Myocardial Infarction; Randomized Contro

2004
Rofecoxib and dental prescribing.
    British dental journal, 2004, Nov-13, Volume: 197, Issue:9

    Topics: Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Pharmacopoeias as Topic; Stroke;

2004
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; C

2005
Lessons learned after the withdrawal of rofecoxib.
    Managed care interface, 2004, Volume: 17, Issue:11

    Topics: Clinical Trials as Topic; Cyclooxygenase Inhibitors; Decision Making, Organizational; Humans; Lacton

2004
UK patients seek compensation after taking rofecoxib.
    BMJ (Clinical research ed.), 2004, Dec-04, Volume: 329, Issue:7478

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Compensation and Redress; Humans; La

2004
Vioxx removed from market.
    Mayo Clinic women's healthsource, 2004, Volume: 8, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Myocardial Infarction; Stroke; Sulfones

2004
COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
    The American journal of managed care, 2004, Volume: 10, Issue:11 Pt 1

    Topics: Contraindications; Cyclooxygenase Inhibitors; Drug Industry; Humans; Lactones; Myocardial Infarction

2004
[Rofecoxib (Vioxx) has been withdrawn, what next?].
    Duodecim; laaketieteellinen aikakauskirja, 2004, Volume: 120, Issue:21

    Topics: Dose-Response Relationship, Drug; Drug and Narcotic Control; Finland; Forecasting; Humans; Lactones;

2004
The sad story of Vioxx, and what we should learn from it.
    Cleveland Clinic journal of medicine, 2004, Volume: 71, Issue:12

    Topics: Arthritis, Rheumatoid; Drug Approval; Drug Industry; Humans; Lactones; Myocardial Infarction; Produc

2004
FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke.
    BMJ (Clinical research ed.), 2005, Feb-26, Volume: 330, Issue:7489

    Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Membrane

2005
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Science (New York, N.Y.), 2005, Feb-25, Volume: 307, Issue:5713

    Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cy

2005
The lessons of Vioxx.
    Cutis, 2005, Volume: 75, Issue:1

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis

2005
Drug safety special: the safety catch.
    Nature, 2005, Mar-31, Volume: 434, Issue:7033

    Topics: Adverse Drug Reaction Reporting Systems; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; He

2005
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
    Drug safety, 2006, Volume: 29, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib;

2006
Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Circulation, 2006, May-09, Volume: 113, Issue:18

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug

2006
Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
    Circulation, 2006, May-09, Volume: 113, Issue:18

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug

2006
Celecoxib shown effective in preventing colon polyps.
    Journal of the National Cancer Institute, 2006, May-17, Volume: 98, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib

2006
[Overestimated].
    Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topi

2006
Long-term risk of ischemic stroke associated with rofecoxib.
    Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:2

    Topics: Adenomatous Polyps; Brain Ischemia; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Female; Follo

2007
Cerebrovascular events after discontinuation of rofecoxib treatment.
    Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:2

    Topics: Brain Ischemia; Cyclooxygenase 2 Inhibitors; Humans; Incidence; Lactones; Risk; Stroke; Sulfones

2007
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
    Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coh

2008
FDA warns Merck over its promotion of rofecoxib.
    BMJ (Clinical research ed.), 2001, Oct-06, Volume: 323, Issue:7316

    Topics: Anticoagulants; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Drug Interactio

2001
Is concern about cardiovascular events with the new coxib class of drugs justified?
    Medscape women's health, 2001, Volume: 6, Issue:5

    Topics: Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Drug Evaluation; Humans; Lac

2001